LONDON--(BUSINESS WIRE)--Tenpoint Therapeutics (“Tenpoint”), a biotechnology company pursuing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ...

The TenPoint Flatline 460 isn’t the fastest, lightest, or even most accurate crossbow I’ve tested, but it is one of the few that does everything well. Like five fingers that become a fist, this ...

I’ve tested dozens of crossbows over the last four years — including the fastest, most compact, and most expensive on the market. But, what impresses me the most is a crossbow that’s accurate, has ...

Oppenheimer & Co.’s 2025 Biotech in the Berkshires is being held on August 4–6 in the Berkshires, MA. Tenpoint Therapeutics' President and Chief Business Officer Ben Bergo and Melissa Epperly, Chief ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tenpoint Therapeutics has launched with a $70 million ...

Eye-focused biotechs Tenpoint Therapeutics and Visus Therapeutics are joining forces, setting their sights on filing a new drug approval application next year for a presbyopia-correcting eye drop.

In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients with presbyopia for up to eight hours. The top-line results come from ...

If prompted for JonesTrading contact, please reference Moderator and Director, Biotech Equity Research Analyst, Debanjana Chatterjee, PhD. The live webcast can be ...

Please provide your email address to receive an email when new articles are posted on . The submission is supported by positive data from the phase 3 BRIO-I and BRIO-II studies. If approved, Brimochol ...